Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study

Gargano, Giuliana; Agnese, Valentina; Calò, Valentina; Corsale, S; Augello, Claudia; Bruno, L; Paglia, Laura La; Gullo, A; Ottini, Laura; Fulfaro, Fabio; Rinaldi, Giulia; Crosta, A; Cicero, Giuseppe; Majorana, O.; Palmeri, Laura; Cipolla, C; Agrusa, Antonino; Gulotta, Gaspare; Morello, Vincenza; Fede, Giuseppe Di; Adamo, Vincenzo; Colucci, Giuseppe; Rm, Tomasino; Valerio, Maria Rosaria; Bazan, V.; Russo, Antonio

doi:10.1093/annonc/mdl948

Cited by 18 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MGB1 detection could be improved by using an epithelial cell enrichment step with immunomagnetic beads as has been reported by other investigators (18). MGB1 detection rates in early breast cancer have varied considerably in published studies from 2% to 22% (23,24,38,39). This variation can be attributed to the different detection techniques used with different sensitivities and specificities, the different patient populations studied, and possibly the lack of correlation data about MGB1 expression in the primary tumor.…”

Section: Discussionmentioning

confidence: 88%

Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer

Ignatiadis¹,

Kallergi²,

Ntoulia

et al. 2008

Clinical Cancer Research

216

156

View full text Add to dashboard Cite

Purpose: To investigate the prognostic value of the molecular detection of circulating tumor cells (CTCs) using three markers [cytokeratin 19 (CK19), mammaglobin A (MGB1), and HER2] in early breast cancer. Experimental Design: CK19mRNA+, MGB1mRNA+, and HER2mRNA+ cells were detected using real-time (CK19) and nested (MGB1 and HER2) reverse transcription-PCR in the peripheral blood of 175 women with stage I to III breast cancer before the initiation of adjuvant chemotherapy. The detection of CTCs was correlated with clinical outcome. In 10 patients, immunofluorescence staining experiments were done to investigate the coexpression of cytokeratin, MGB1, and HER2 in CTCs. Results: CK19mRNA+, MGB1mRNA+, and HER2mRNA+ cells were detected in 41.1%, 8%, and 28.6% of the 175 patients, respectively. Patients had one of the following molecular profiles: CK19mRNA+/MGB1mRNA+/HER2 mRNA+ (n = 8), CK19mRNA+/MGB1mRNA+/ HER2mRNA-(n = 1), CK19mRNA+/MGB1mRNA-/HER2mRNA+ (n = 42), CK19mRNA+/ MGB1mRNA-/HER2mRNA-(n = 21), CK19mRNA-/MGB1mRNA+/HER2mRNA-(n = 5), and CK19mRNA-/MGB1mRNA-/HER2mRNA-(n = 98). Double-immunofluorescence experiments confirmed the following CTC phenotypes: CK+/MGB1+, CK+/MGB1-, CK-/MGB1+, CK+/ HER2+, CK+/HER2-, MGB1+/HER2-, and MGB1+/HER2+. In univariate analysis, the detection of CK19mRNA+, MGB1mRNA+, and HER2mRNA+ cells was associated with shorter diseasefree survival (DFS; P < 0.001, P = 0.001, and P < 0.001, respectively), whereas the detection of CK19mRNA+ and MGB1mRNA+ cells was associated with worse overall survival (P = 0.044 and 0.034, respectively). In multivariate analysis, estrogen receptor^negative tumors and the detection of CK19mRNA+ and MGB1mRNA+ cells were independently associated with worse DFS. Conclusion: The detection of peripheral blood CK19mRNA+ and MGB1mRNA+ cells before adjuvant chemotherapy predicts poor DFS in women with early breast cancer.

show abstract

Section: Discussionmentioning

confidence: 88%

Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer

Ignatiadis¹,

Kallergi²,

Ntoulia

et al. 2008

Clinical Cancer Research

216

156

View full text Add to dashboard Cite

show abstract

“…Recently, quantitative real-time fluorescence-based RT-PCR has become the ideal method for the detection of RNA [43]. Some studies have applied this methodology in the analysis of mammaglobin mRNA expression in peripheral blood samples of breast cancer patients and still reported low sensitivity [36,44]. Although real-time RT-P CR allows the quantification of the transcript of interest, conventional RT-PCR is still a good method for a prospective study with a high number of samples.…”

Section: Discussionmentioning

confidence: 99%

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Marques

Teixeira

Diamond

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

International audienceHuman mammaglobin (hMAM) mRNA is a sensitive and specific marker of breast cancer cells. We evaluated if hMAM mRNA detection in serial peripheral blood samples from non-metastatic breast cancer patients predicts for disease recurrence. Patients scheduled for adjuvant or neoadjuvant chemotherapy were eligible. Serial blood samples were collected up to 5 years, the first before (neo)adjuvant chemotherapy. hMAM gene expression was analysed by RT-PCR. Specificity was evaluated in blood samples from healthy volunteers. A total of 321 patients were included. The incidence of pre-chemotherapy hMAM-positive samples was similar in patients who latter experienced cancer recurrence (22.4%) and those who remained disease-free (17.9%; = 0.46). Similarly, the mean number of positive follow-up samples was similar in both groups (0.15 ± 0.22 and 0.13 ± 013; = 0.29). Furthermore, there was no difference in disease-free (= 0.63) or overall survival (= 0.57) in patients with and without positive baseline samples or between patients whose follow-up samples were always hMAM negative and those with at least one positive sample. Multivariate survival analysis confirmed that hMAM mRNA detection before or after (neo)adjuvant chemotherapy was not predictive of recurrence. There is no evidence that hMAM mRNA detection at diagnosis or during follow-up predicts for breast cancer recurrence

show abstract

“…However, it has not yet been proven if the use of robotic surgery result in better clinical outcomes than conventional laparoscopy (22). Several recent studies support the use of robotic surgery in gynecologic oncology (23,24) and in the correction of pelvic floor defects. The RSC was introduced in 2004 as the last step in the evolution of minimally invasive surgery (25).…”

Section: Discussionmentioning

confidence: 99%

Robotic versus laparoscopic sacrocolpopexy for apical prolapse: a case-control study

Cucinella¹,

Calagna²,

Buono³

et al. 2016

GCHIR

View full text Add to dashboard Cite

The apical prolapse has always been considered the most complex of the defects of the pelvic floor, for both the difficulty of the surgical corrective technique and for the high post-surgical recurrence rate. This is a fairly frequent pathological condition. It is estimated that in her life 1/10 women undergoes a hysterectomy and up to 10% of these requiring surgical correction of apical prolapse (1). The standard treatment for surgical management of apical prolapse is abdominal sacrocolpopexy (ASC) (2). The progress made in the field of laparoscopic surgery in the past decades and the numerous literature reports that confirmed the considerable advantages respect to abdominal open surgery, allowed the spread of laparoscopic sacrocolpopexy (LSC). The technique was introduced in 1994 by Nezhat, integrating the experience of open conventional surgery with the advantages of minimally invasive approach, in order to minimize morbidity and accelerating the recovery of patients (3). Today, the LSC can be considered the standard treatment for apical prolapse. Several studies over the years have compared the laparoscopic approach with the open abdominal surgery. LSC is associated with less intra-operative blood loss, reduction in post-operative pain and a shorter hospital stay (4). Currently, with reference to minimally invasive surgery the most advanced and sophisticated tool available is the DaVinci Surgical System (Intuitive Surgical Inc., Sunnyvale, California, USA). The robotic surgical systems have been developed with the aim of facilitating the technically difficult procedures: the 3D-HD vision system, the use of a dedicated console and instruments with great flexibility and precision of the movements, also allow the execution of the most complex surgical maneuvers, acheiving excellent results. In the last years, several surgical operations were performed with robotic system, like robotic-assisted sacral colpopexy SUMMARY: Robotic versus laparoscopic sacrocolpopexy for apical prolapse: a case-control study.

show abstract

Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study

Abstract: Our preliminary results demonstrate that the detection of MGB1 transcript in peripheral blood of BC patients was specific but with low sensitivity. MGB1 overexpression by itself or in combination with Ki67 might be considered an index of BC progression.

Cited by 18 publications

References 16 publications

Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer

Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Robotic versus laparoscopic sacrocolpopexy for apical prolapse: a case-control study

Contact Info

Product

Resources

About